Search clinical trials for: MK-8521 100/150μg

Total 128 results

Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)

Renal Impairment
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Merck Sharp & Dohme LLC

Completed

MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)

Human Immunodeficiency Virus

Romania, South Africa
Merck Sharp & Dohme LLC

Completed

A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)

Human Immunodeficiency Virus | AIDS Virus

Romania
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)

Overactive Bladder
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Afferent Pharmaceuticals, Inc.

Completed

Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)

Refractory Chronic Cough
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Neoplasms, Advanced
Merck Sharp & Dohme LLC

Terminated

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Type 2 Diabetes
VelosBio Inc.

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)

Gastric Cancer | Pancreatic Cancer | NSCLC | Platinum-resistant Ovarian Cancer | Triple-negative Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Non-squamous Non-small-cell Lung Cancer | Estrogen-receptor-positive Breast Cancer | Progesterone-receptor-positive Breast Cancer | Estrogen-receptor-negative... and other conditions

United States, Canada
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
Merck Sharp & Dohme LLC

Terminated

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Type II Diabetes Mellitus
VelosBio Inc., a subsidiary of Merck & Co., Inc...

Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

Follicular Lymphoma | Acute Myeloid Leukemia | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Acute Lymphoid Leukemia | Richter Transformation Lymphoma | Lymphoplasmacytoid Lymphoma | T-cell Non-Hodgkin...

United States
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Shenzhen Kangzhe Pharmaceutical Co., Ltd.

Completed

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

Plaque Psoriasis

China
Bayer

Completed

Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.

Pulmonary Disease, Chronic Obstructive | Hypertension, Pulmonary

Germany
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Tolerability of MK-0517 in Healthy Subjects (MK-0517-012)

Postoperative Nausea and Vomiting | Chemotherapy-Induced Nausea and Vomiting
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); CONRAD

Completed

Safety and Acceptability Study of the UC-781 Microbicide Gel Applied Rectally

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

Hepatitis C Virus (HCV) Infection

France
Merck Sharp & Dohme LLC

Active, not recruiting

A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Urothelial Carcinoma

Australia, United States, Chile, Denmark, Israel, Korea, Republic of, Spain
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

Human Immunodeficiency Virus (HIV) Infection

United States
Merck Sharp & Dohme LLC

Withdrawn

A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)

Human Immunodeficiency Virus (HIV) Infections
Merck Sharp & Dohme LLC

Not yet recruiting

Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)

HIV | Human Immunodeficiency Virus
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

Human Immunodeficiency Virus (HIV) Infection

United States, Germany
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

HIV-1 Infection

United States, Israel, South Africa
Pfizer
Merck Sharp & Dohme LLC

Completed

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

Renal Cell Carcinoma

United States
Hamad Medical Corporation

Terminated

Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia (DANIN)

Chronic Myeloid Leukemia - Chronic Phase

Qatar
Merck Sharp & Dohme LLC

Active, not recruiting

Dose Ranging, Switch Study of Islatravir (ISL) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

HIV-1 Infection

United States, France, Switzerland
Sun Pharmaceutical Industries Limited

Withdrawn

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Plaque-type Psoriasis
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Organon and Co

Completed

MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)

Hypertension
Sun Pharmaceutical Industries Limited

Completed

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) (reSURFACE 1)

Plaque Psoriasis
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)

Hypercholesterolemia
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Active, not recruiting

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Bladder Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Islatravir and Methadone Pharmacokinetics (MK-8591-029)

HIV-1 Infection

United States
Medical University of Graz

Completed

Probiotics in Diabesity: A Pilot Study (Diabesity)

Obesity | Diabetes

Austria
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Triple Negative Breast Neoplasms

Colombia, United States, Canada, Chile, France, Germany, Hungary, Ireland, Japan, Korea, Republic of, Poland, Spain, Taiwan, Ukraine, United Kingdom
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Metastatic Breast Cancer

United States, Taiwan, Korea, Republic of, China, India
Merck Sharp & Dohme LLC

Recruiting

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Israel, United States, Australia

3

Subscribe